The International Diabetes Federation (IDF) Task Force on Epidemiology and Prevention has highlighted the importance of the link between type 2 diabetes and obstructive sleep apnoea (OSA).

Recent research findings demonstrating the relation between type 2 diabetes and OSA were presented at the American Diabetes Association 68th Annual Scientific Sessions, inciting further study on the subject within the medical community.

Professor Paul Zimmet, co-chair of the IDF Task Force on Epidemiology and Prevention, said: "While type 2 diabetes is recognised as a serious global epidemic, the severe health consequences of untreated sleep apnea, especially in people with diabetes, are not."

Figures show that as many as 40 per cent of patients with OSA also suffer from diabetes.

According to experts, studies have indicated that the prevalence of cardiovascular disease increases in tandem with the progression of OSA, meaning that people with diabetes and/or OSA are at higher risk of cardiovascular problems.

Co-chair professor Sir George Alberti added that although the exact mechanisms associating OSA with diabetes are not yet fully understood, the significant consequences of both conditions require the attention of medical professionals and researchers worldwide.

Login and visit the Diabetes Knowledge Centre

• Porridge could limit type-2 diabetes side effects 09/01/09
• Men with type-2 diabetes at greater risk of cardiovascular death 06/01/09
• Decline in mental processing affects diabetes patients, study reveals 05/01/09
• Leptin study could lead to new diabetes treatment 23/12/08
• Symptomless virus linked with type 1 diabetes 19/12/08

• PRANDIN Tablets - 49.44%
  ... in patients with Type 2 diabetes (Non Insulin-Dependent Diabetes Mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in Type 2 diabetes patients who are not ...
  
  
• DDAVP - 49.42%
  ... and treatment of vasopressin-sensitive cranial diabetes insipidus; establishing renal concentration capacity. DDAVP Tablets: Treatment of vasopressin-sensitive cranial diabetes insipidus; treatment of post-hypophysectomy polyuria/ polydipsia. DDAVP/Desmopressin Injection: Cranial diabetes insipidus ...
  
  
• JANUVIA Film-Coated Tablets - 47.95%
  JANUVIA is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin when diet and exercise, plus metformin do not provide adequate glycaemic control. For patients with type 2 diabetes mellitus in whom use of a PPAR? agonist (i.e. a ...
  
  
• EXUBERA - 47.95%
  ... for the treatment of adult patients with type 2 diabetes mellitus not adequately controlled with oral antidiabetic agents and requiring insulin therapy. EXUBERA is also indicated for the treatment of adult patients with type 1 diabetes mellitus, in addition to long or intermediate acting ...
  
  
• NOCUTIL - 47.95%
  Treatment of idiopathic central diabetes insipidus, or diabetes insipidus occurring after hypophysectomy, cranial trauma, or surgery in the pituitary region ...
  
  
• GLUCOPHAGE - 47.95%
  Non-insulin dependent (type II) diabetes either alone or with sulphonylureas. Adjuvant therapy in insulin-dependent diabetes, particularly in the obese ...